About Us

  1. TOP
  2. Company


Company NameiPS Portal, Inc
FoundedJuly 31, 2014
CEO & COOMasakazu Kobayashi
AddressLouis Pasteur Center for Medical Reserch, Bldg., 103-5 Tanaka Monzen-cho , Sakyo-ku, Kyoto 606-8225, Japan
Capital831 million Yen (capital stock of 99 million Yen, and capital reserve of 732 million Yen)
Number of employees 20

Corporate Governance

Director & Auditor
Masakazu Kobayashi
Managing Director CFO
Takasei Yoshida
Managing Director
Hisako Kubo
Managing Director
Hirotomo Kawano
Managing Director
Yoshio Yamaoka
Professor Emeritus, Kyoto University
Managing Director
Junya Toguchida
Professor & Adviser Center for iPS Research and Application(CiRA)Kyoto University
Cooperative Professor Institute for Life and Medical Sciences, Kyoto University
Corporate Auditor
Kozo Miseki
Corporate Auditor
Yoshito Fujikawa
Attorney at Law ,Patent Attorney
Advisory Board
Scientific Advisory Board Kenji Osafune, Professor, Center for iPS Cell Research and Application, Kyoto University
Kohji Nishida, Professor & Chairman, Department of Ophthalmology, Graduate School of Medicine, Osaka University
Management Advisory Board Motoshige Ito, Emeritus Professor, The University of Tokyo
Consultants Masahiro Kino-oka, Professor, Graduate School of Engineering Osaka University
Pharmaceutical Affairs Consultants Shin Kawamata, Project Professor, Graduate School of Science, Technology and Innovation, Kobe University
Zen-ichi Mohri, Regenerative Medicine Advisor for Development


iPS Portal Inc. began operations in September 2014, following the transfer of non-patent related operations of iPS Academia Japan, Inc. At the time of its establishment, iPS Portal Inc. focused on contract testing of iPS cells in efforts to promote the broad use of iPS cell technology. We also provide support for start-up companies related to Cell-Technology, and have been involved in the establishment and operation of Raymei, Inc., a corneal regenerative medicine company since 2016 and Houjou, Inc., a company that aims to protect endangered species and to commercialize fertility treatments since 2020. In January 2021, we moved our headquarters and laboratory to a new location, marking the next stage of our business.We will continue to contribute to the development of the life science field by supporting iPS cells and other Cell-Technology-based research and business from both technology and business perspectives, and by providing higher value-added services.


Please feel free to contact us if you have any questions or consultation.